<DOC>
	<DOCNO>NCT00705627</DOCNO>
	<brief_summary>Locoregionally advanced nasopharyngeal carcinoma ( NPC ) ( stage III , IV UICC 2002 Classification ) divide two group accord risk metastasis : high-risk metastasis group ( T4 N2-3 ) low-risk metastasis group ( T3N0-1 ) . In low-risk metastasis group , concurrent chemoradiotherapy ( CCRT ) might decrease local recurrence distance metastasis , benefit overall survival . On hand , neoadjuvant chemotherapy also associate low distance metastasis advance stage NPC . Nevertheless , CCRT alone neoadjuvant chemotherapy alone lead unsatisfactory result regard distance metastasis patient high-risk metastasis group . In case , utmost important investigate new treatment combine neoadjuvant chemotherapy plus CCRT order improve overall survival locoregionally advanced NPC high-risk metastasis . In study , order investigate effect adverse reaction neoadjuvant chemotherapy plus CCRT distance metastasis locoregionally relapse , four hundred patient high risk distance metastasis randomly divide two group , compare neoadjuvant chemotherapy ( DDP+5FU ) plus CCRT ( DDP ) CCRT ( DDP ) alone . We aim find best therapeutic regimen low adverse reaction NPCS high risk distance metastasis .</brief_summary>
	<brief_title>A Multicenter Trial Comparing Multi-course Chemotherapy Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nasopharyngeal carcinoma , include WHO II III Original clinical stage must T4 N23 （UICC 2002） Male pregnant female Age 1860 WBC ≥4,000/mm3 PLT ≥ 100,000/mm3 With normal liver function test ( ALT、AST≤2.5×ULN ) With normal renal function test ( Creatinine ≤ 1.5×ULN ) Performance status scale ECOG grade 0，1 Without radiotherapy chemotherapy Patients must give sign informed consent Patients evidence relapse distant metastasis The presence uncontrolled lifethreatening illness Receiving way anticancer therapy Receiving radiotherapy chemotherapy Investigator consider patient ca n't finish whole study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>concurrent chemotherapy</keyword>
	<keyword>randomize control clinical trial</keyword>
</DOC>